Synapse - Allison Betof Warner

Search Within

Allison Betof Warner

Results (76)

Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM)

Meeting Abstract

Bai, X.; Shoushtari, A. N.; Warner, A. B.; Quach, H.; Cann, C. G.; Zhang, M.; Pallan, L.; Harvey, C.; Si, L.; Tang, B.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB)

Meeting Abstract

Loo, K.; Goldman, D. A.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Dermatologic infections in cancer patients treated with checkpoint inhibitors

Journal Article

Do, M. H.; Barrios, D. M.; Phillips, G. S.; Postow, M. A.; Warner, A. B.; Rosenberg, J. E.; Noor, S. J.; Markova, A.; Lacouture, M. E.
Journal of the American Academy of Dermatology (2021)

Fulltext@MSK | Save

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

Journal Article

Chapman, P. B.; Jayaprakasam, V. S.; Panageas, K. S.; Callahan, M.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; Betof Warner, A.
Journal for ImmunoTherapy of Cancer (2021)

Fulltext@MSK | Save

Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy

Journal Article

Bai, X.; Hu, J.; Betof Warner, A.; Quach, H. T.; Cann, C. G.; Zhang, M. Z.; Si, L.; Tang, B.; Cui, C.; Yang, X.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Immune checkpoint inhibitors in patients with pre-existing psoriasis: Safety and efficacy

Journal Article

Halle, B. R.; Betof Warner, A.; Zaman, F. Y.; Haydon, A.; Bhave, P.; Dewan, A. K.; Ye, F.; Irlmeier, R.; Mehta, P.; Kurtansky, N. R.; more...
Journal for ImmunoTherapy of Cancer (2021)

Fulltext@MSK | Save

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness

Journal Article

Hirschhorn, D.; Betof Warner, A.; Maniyar, R.; Chow, A.; Mangarin, L. M. B.; Cohen, A. D.; Hamadene, L.; Rizzuto, G. A.; Budhu, S.; Suek, N.; more...
JCI Insight (2021)

Fulltext@MSK | Save

LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade

Journal Article

Shen, R.; Postow, M. A.; Adamow, M.; Arora, A.; Hannum, M.; Maher, C.; Wong, P.; Curran, M. A.; Hollmann, T. J.; Jia, L.; more...
Science Translational Medicine (2021)

Fulltext@MSK | Save

A phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors

Meeting Abstract

Gettinger, S.; Kluger, H.; Schoenfeld, A.; Betof-Warner, A.; He, K.; Sukari, A.; de Speville Uribe, B. D.; Lee, S.; Haefliger, S.; Goldberg, Z.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model

Meeting Abstract

Betof Warner, A.; Hirschhorn, D.; Mangarin, L. M.; Hamadene, L.; Cohen, A. D.; Rizzuto, G. A.; Wolchok, J. D.; Merghoub, T.
Cancer Research (2021)

Fulltext@MSK | Save